Syapse Precision Medicine Platform Selected by Leading Oncology Society to Enable Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Posted by: Andro Hsu 06/01/2015

[If your organization is interested in becoming a TAPUR site, please visit ASCO's TAPUR website for more information.]

PALO ALTO, Calif., June 1, 2015 – Syapse, the leading provider of precision medicine software, announced today that its Syapse Precision Medicine Platform was selected by the American Society of Clinical Oncology (ASCO) to automate clinical workflows for the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. This groundbreaking clinical trial will provide qualifying cancer patients who lack standard treatment options access to molecularly-targeted medications outside of their Food and Drug Administration (FDA) approved indications, and will track treatment courses and outcomes. Using the Syapse platform, practices participating in TAPUR can integrate study participants’ genomic profile, treatment history, and clinical outcomes and report the data to the researchers. The Syapse platform will also support the work of the TAPUR Molecular Tumor Board.

Syapse Precision Medicine Platform will enable the TAPUR study to standardize study workflows that include retrieval and review of molecular test results, and case review by the study’s Molecular Tumor Board. Structured data from a growing network of participating health networks will be centralized in Syapse, becoming an actionable resource for the TAPUR study team, allowing them to better identify signals of drug activity.

“The ability to integrate and standardize clinical and molecular data collected from participating research networks and labs across the nation is key to the study’s success,” said ASCO Chief Medical Officer Richard L. Schilsky, MD, FASCO. “Syapse’s platform will empower ASCO’s TAPUR study to document the real-world experiences of participating patients and identify potential new uses of already available targeted therapies.”

“Syapse Precision Medicine Platform is designed to enable provider institutions to scale their precision oncology programs,” said Jonathan Hirsch, Founder and President of Syapse. “We are excited to collaborate with ASCO to enable the groundbreaking TAPUR study, which will advance precision medicine by building an evidence base for the utility of matching targeted off-label therapies to genomic test results.” 

About Syapse

Syapse software enables healthcare providers to deploy precision medicine programs. Leading academic and community healthcare providers use the Syapse Precision Medicine Data Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The Social+Capital Partnership and Safeguard Scientifics (NYSE:SFE). For more information, visit www.syapse.com.